Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05219695
Other study ID # AAAS9859
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 19, 2022
Est. completion date May 2025

Study information

Verified date May 2024
Source Columbia University
Contact Elisa Konofagou, PhD
Phone 212-342-0863
Email ek2191@columbia.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to demonstrate the initial clinical feasibility of using Harmonic Motion Imaging (HMI) for Focused Ultrasound Surgery (FUS) guidance and monitoring in patients with benign and stage 1 non-metastatic breast cancers. The investigators hypothesize that changes in HMI parameters will inform progression of FUS ablation.


Description:

Patients with small solid tumors without positive lymph nodes have the highest survival rate. However, especially for patients with benign tumors (most common in younger women) and older patients (>65 years old) who fit these criteria, an alternative treatment technique that is less invasive than the current surgical or invasive ablative intervention may be more beneficial. FUS is a noninvasive, non-ionizing treatment procedure that precisely focuses and delivers a large amount of ultrasound energy to the target area, causing localized temperature rise and cell necrosis at the target. The main advantage of focused ultrasound ablation (FUS) is that it avoids surgery. Without surgery, recovery from the procedure is much faster, patients may experience less pain, and cosmetological results may be improved. The efficacy and safety of FUS rely heavily on treatment monitoring. Treatment imaging techniques currently used include MRI and ultrasound Bmode imaging. Magnetic resonance imaging (MRI) thermometry is used to detect the temperature rise across the FUS treatment area. However, MRI guidance can be expensive and time-consuming compared to ultrasound-based HIFU guidance methods. Conventional B-mode based 'hyperecho' tracking can be challenging for HIFU monitoring, as it is sensitive to cavitation, which occurs at high temperatures. HMI is an ultrasound elasticity method that can provide measurements of the locally generated mechanical response and inherent mechanical properties of tissues . The result is a new image that contains unique localized information on the relative stiffness in and around the tumor. The investigators have shown in pre-clinical data that HMI has the ability to monitor mechanical changes in tissue that occur with ablation. The combination of FUS with HMI monitoring is termed HMI guided FUS, or HMIgFUS. This study aims to evaluate the HMI technique for monitoring FUS ablation in a clinical setting. Eligible and consenting patients will be imaged using HMI, and then will undergo HMIgFUS at a central position inside the tumor. The tumor will be imaged using HMI again following ablation. Following our study, the patients will undergo their scheduled surgery. The purpose of this study is to evaluate HMIgFUS in a lower risk setting, as the tumor will be excised following our study, to better inform future studies, in which surgery may not be needed.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date May 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Women age =18 - Patients with fibroadenoma (benign tumor) or early-stage, non-metastatic breast cancer (stage I without the involvement of axillary lymph nodes) - Scheduled to receive surgical resection of the tumor by the clinical care team (ideal target lesion upper boundary should be deeper than 1 cm below the skin, and the ideal size of the lesion should be 2-5 cm in diameter) Exclusion Criteria: - Pregnant or lactating women - Patients with breast implants - Patients with a history of laser or radiation therapy to the targeted breast - Patients who have received or are scheduled to receive thermal ablation or treatment of the tumor (other than surgery) as part of clinical care

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Harmonic motion imaging guided focused ultrasound (HMIgFUS)
Harmonic motion imaging guided focused ultrasound (HMIgFUS) is a combined treatment and imaging method, in which focused ultrasound (FUS) is used to thermally ablate tissue and harmonic motion imaging (HMI) is used for FUS guidance and monitoring. FUS applies high intensity focused ultrasound waves at its specified target to heat the tissue over a specified duration, causing cell death at the target area. HMI is an elasticity imaging technique which induces dynamic tissue vibrations at the target for tissue elasticity characterization. One of the inclusion criteria for this study is that participants must be scheduled for surgical excision of their breast tumor. In this study, HMIgFUS will be applied to anesthetized participants immediately prior to their scheduled surgery. HMI imaging will also be performed immediately prior to and after HMIgFUS application.

Locations

Country Name City State
United States Columbia University Irving Medical Center/NYP New York New York

Sponsors (1)

Lead Sponsor Collaborator
Columbia University

Country where clinical trial is conducted

United States, 

References & Publications (2)

Han Y, Wang S, Hibshoosh H, Taback B, Konofagou E. Tumor characterization and treatment monitoring of postsurgical human breast specimens using harmonic motion imaging (HMI). Breast Cancer Res. 2016 May 9;18(1):46. doi: 10.1186/s13058-016-0707-3. — View Citation

Han Y, Wang S, Payen T, Konofagou E. Fast lesion mapping during HIFU treatment using harmonic motion imaging guided focused ultrasound (HMIgFUS) in vitro and in vivo. Phys Med Biol. 2017 Apr 21;62(8):3111-3123. doi: 10.1088/1361-6560/aa6024. Epub 2017 Mar 21. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with ablation To identify markers of ablation progression using HMIgFUS images, thereby predicting whether ablation occurred or not. The investigators will also use differences in HMI imaging performed before and after ablation to assess the presence of ablation. The results from both of these methods will be validated with pathological findings, to determine whether ablation was achieved. From the date of ablation and imaging to the date of pathological results (approximately 1 week)
Primary R2 value of ablated lesion depth The depth of the lesion (in mm away from the surface of the skin) as shown on HMIgFUS images will be compared and validated with pathological findings. From the date of ablation and imaging to the date of pathological results (approximately 1 week)
Primary R2 value of ablated lesion width The width of the lesion (in mm laterally across the lesion) as shown on HMIgFUS images will be compared and validated with pathological findings. From the date of ablation and imaging to the date of pathological results (approximately 1 week)
Primary R2 value of ablated lesion area The area of the lesion (in mm^2) as shown on HMIgFUS images will be compared and validated with pathological findings. From the date of ablation and imaging to the date of pathological results (approximately 1 week)
See also
  Status Clinical Trial Phase
Recruiting NCT05528263 - Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial) N/A
Recruiting NCT06064812 - A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC. Phase 1
Terminated NCT04088435 - Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer
Terminated NCT03723863 - Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy N/A
Completed NCT00393341 - Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer N/A
Active, not recruiting NCT04180579 - Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients N/A
Recruiting NCT06275126 - Optimizing Surgical Decisions in Young Adults With Breast Cancer N/A
Not yet recruiting NCT05724758 - Patient Reported Outcomes After Oncoplastic Breast Conserving Surgery
Active, not recruiting NCT03766009 - Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making N/A
Recruiting NCT05406531 - The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors N/A
Recruiting NCT05861271 - Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer Phase 2
Recruiting NCT05898789 - Virtual Rehabilitation for Cancer Survivors N/A
Recruiting NCT06006806 - Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy N/A
Active, not recruiting NCT03927027 - Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection Phase 3
Recruiting NCT05288777 - Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer Phase 2/Phase 3
Not yet recruiting NCT06336538 - Abbreviated MBCT for Depression in Older African American/Black Breast Cancer Survivors N/A
Not yet recruiting NCT05887154 - Non Surgical Treatment (Microwave Ablation) of Breast Cancer N/A
Completed NCT02639208 - Novel Social Media Intervention For Older Br CA Patients N/A
Not yet recruiting NCT06268665 - Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Phase 2
Completed NCT02335671 - Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy N/A